Beta Blockers

Amino-alcohols, other than those containing more than one kind of oxygen function, their ethers and esters, salts therof, nesoi

Applications Bemotrizinol is a broad-spectrum UV absorber, absorbing both UVA and UVB. Bemotrizinol is added to various sunscreens to absorb UV rays. References Couteau, C., et al.: Int. J. Pharmaceutics., 437, 250 (2012); Lacatusu, I., et al. Nanoscale. Res. Lett., 6, 73 (2011);

Impurity Atorvastatin EP Impurity F Stability Hygroscopic Applications Atorvastatin (A791750) impurity. References Graul, A., et al.: Drugs Fut., 22, 956 (1997),

Applications Manidipine Dihydrochloride is a metabolite of Manidipine (M164000), a dihydropyridine calcium channel blocker that exhibits antihypertensive properties. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Meguro, K., et al.: Chem. Pharm. Bull., 33, 3787 (1985), Mizuno, K., et al.: Curr. Ther. Res., 52, 248 (1992); Hosaka, S., et al.: Chem. Pharma. Bulletin., 55, 793 (2007);

Applications Desacetyl Diltiazem-d4 Hydrochloride is the labeled analogue of Desacetyl Diltiazem Hydrochloride (D289335), a metabolite of Diltiazem Hydrochloride (D460620), a calcium channel blocher with vasodilating activity. Antianginal; antihypertensive; antiarrhythmic (class IV). References Shallcross, H., et al.: Br. Med. J., 295, 1236 (1987); Yeung, P.K.F., et al.: Drug Metab. Dispos., 18, 1055 (1990); Cashman, J.R., et al.: J. Med. Chem., 34,2049 (1991); Sato, et al.: Arzneim.-Forsch., 21, 1338 (1971); Smirnov, S.R.: Eur. J. Pharmacol., 360, 81 (1998); Hansson, L., et al.: Lancet, 356, 359 (2000)

Diagnostic or lab reagents on a backing, prepared diagnostic or lab reagents whether or not on a backing, whether or not in the form of kits, nesoi

Impurity Dilitiazem EP Impurity D Stability Hygroscopic Applications N-Desmethyl Diltiazem Hydrochloride (Dilitiazem EP Impurity D) is a metabolite of Diltiazem (D460620), an antianginal and an antihypertensive pharmaceutical. Diltiazem regulates calcium release from intracellular stores in neutrophils. References Li, R., et al.: J. Med. Chem., 35, 3246 (1992),

Stability Hygroscopic Applications A labelled metabolite of Lovastatin.

Applications Isotope labelled Dicumarol is a natural chemical used as an anticoagulant agents that functions as a vitamin K antagonist and is also a derivative of coumarin (C755380). Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Sail, V., et al.: Chem. Biol. Drug. Design., 81, 334 (2013); Zsila, F., et al.: Molec. Pharma., 10, 1668 (2013); Brunhofer, G., et al.: Bioorg. Med. Chem., 20, 6669 (2012);

Diagnostic or lab reagents on a backing, prepared diagnostic or lab reagents whether or not on a backing, whether or not in the form of kits, nesoi

Aromatic drugs of amino-alcohols, other than those contg more than one kind of oxygen function, their ethers and esters; salts thereof, nesoi

Applications (S)-4’-Hydroxywarfarin is the S-enantiomer of the 4’-hydroxyl metabolite of Warfarin (W498500). Formation of (S)-4’-Hydroxywarfarin is increased by quinidine during Warfarin metabolism. References Wong, Y.W.J. et al.: Pharm. Res., 6, 982 (1989); Ngui, J. et al.: Drug Metab. Dispos., 29, 877 (2001);

Impurity Olmesartan Imidazole Ethyl Ester Impurity Applications An Olmesartan (O550000) intermediate. References Sakamoto, F., et al.: Chem. Pharm. Bull ., 32, 2241 (1984), Yanagisawa, H., et al.: J. Med. Chem., 39, 323 (1996),

Applications Used as an antihypertensive and antianginal. A labelled dihydorpyridine calcium channel blocker. References Ali, S.L., et al.: Anal. Profiles Drug Subs., 18, 221 (1989), Soons, P.A., et al.: J. Pharm. Biomed. Anal., 9, 475 (1991), Brown, M.J., et al.: Lancet, 356, 366 (2000),

Applications Antihypertensive; diuretic. References Piala, J.J., et al.: J. Pharmacol. Exp. Ther., 134, 273 (1961), Orzech, C.E., et al.: Anal. Profiles Drug Subs., 7, 297 (1978),

Stability Hygroscopic Applications A metabolite of Nebivolol. References Stoleru, L., et al.: J. Cardiovasc. Pharmacol., 22, 183 (1993), Cockcroft, J., et al.: J. Pharmacol. Exp. Ther., 274, 1067 (1995), Stoschitzky, K., et al.: Cardiovasc. Drugs Ther., 16, 133 (2002), Poole-Wilson, P., et al.: Lancet, 362, 7 (2003),